Patients
14.0 per 100,000 people
Suicide rate, India, 2023 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Vidhi Upadhyay
India Treatment-Resistant Depression Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$67.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $38.2 Mn | — | — |
| 2025 (base) | $42.5 Mn | +$4.2 Mn | — |
| 2026 (forecast) | $47.2 Mn | +$4.7 Mn | +11.1% |
| 2027 (forecast) | $52.4 Mn | +$5.2 Mn | +23.4% |
| 2028 (forecast) | $58.2 Mn | +$5.8 Mn | +37.1% |
| 2029 (forecast) | $64.7 Mn | +$6.5 Mn | +52.4% |
| 2030 (forecast) | $71.9 Mn | +$7.2 Mn | +69.3% |
| 2031 (forecast) | $79.8 Mn | +$8.0 Mn | +88.1% |
| 2032 (forecast) | $88.7 Mn | +$8.9 Mn | +108.9% |
| 2033 (forecast) | $98.6 Mn | +$9.8 Mn | +132.1% |
| 2034 (forecast) | $109.5 Mn | +$10.9 Mn | +157.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $42.5 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $109.5 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug class, route and end user (see all) |
| Key players | Johnson & Johnson, AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Axsome Therapeutics, Compass Pathways (see all) |
| Regulator in India | CDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Treatment-resistant depression drugs help people whose depression has not improved with at least two standard antidepressants.
Key segments of the treatment-Resistant Depression Drugs market include drug class (NMDA Antagonists, Atypical Antipsychotic Add-Ons and Psychedelics) and route (Oral, Intranasal and Intravenous).
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the treatment-Resistant Depression Drugs market. Governments and employers are investing more in mental health care.
Digital tools, new drug classes and care built into primary care and workplaces give the treatment-Resistant Depression Drugs market strong room to grow worldwide.
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the treatment-Resistant Depression Drugs market.
The treatment-Resistant Depression Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.[2] Suicide rate: 14.0 per 100,000 people in 2023, the latest WHO figure for India.[3]
[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 20 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for treatment-Resistant Depression Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.
What doctors and scientists are doing in Treatment-Resistant Depression Drugs right now, from free public sources.
14.0 per 100,000 people
Suicide rate, India, 2023 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
From our blog
India · 3 shared keywords
India · 2 shared keywords
India · 2 shared keywords
India · 2 shared keywords
India · 2 shared keywords
India · 2 shared keywords
OTC & Nutraceuticals · India
Public Health · India
Digital Health · India
Digital Health · India
Public Health · India
Public Health · India